Washington (AP) – An experimental drug made from marijuana successfully reduced back pain in a new study, providing and supporting the ability of the drug in treating one of the most common forms of chronic pain.
The 800-rage study by a German drug manufacturer is the latest evidence of the therapeutic properties of cannabis, which remains illegal under the American federal law, even most states have made it available for medical or recreational use.
Health authorities in Canada and Europe have previously approved a drug-grade form of cannabis for a variety of pain for a variety of pain, including nerve pain due to many sclerosis. In the US, the Food and Drug Administration has approved a drug containing CBD-to treat rare seizures in children with one of the many non-conscious chemicals found in Canbis.
Unlike the drug, known as epidiolax, the new cannabis formula from the Dramekar vertex is THC, which is an active component in Marijuana that users get high. But chemical levels are very low, essentially a microdos, compared to a microdos, is available in other products sold in the sails, chocolate bar and Marizuana dispensary in the US, the company said that patients in the test showed no signs of drug abuse, dependence or return.
Demanding approval for a large group of vertanical patients: people suffering from low back pain, a chronic condition that affects millions and some proven treatment.
Over-the-counter painkiller such as ibuprofen cannot be used for long-term pain due to their side effects, including abdominal ulcers and indigestion. Opioids are not recommended after overprusion of painkopts such as oxicopts in the 1990s and 2000s, causing addiction of addiction to that class of the drug.
Chronic pain is one of the most frequently cited conditions of people enrolled in medical marijuana programs run by the state. But that group has a little harsh research on the use of the drug.
Lead study writer Dr. Mathius Carrst said in an email that new findings suggest that the cannabis can “reduce pain and improve physical function in chronic low-pain patients, usually connected to opioids without safety concerns.” Carrst is a pain specialist at Hannover Medical School and an advisor for vertic.
For new studies, patients with back pain were randomly assigned to take the ownership liquid extracts or placebo of the vertanical.
At the end of 12 weeks, patients taking the drug reported about 2-point deficiency in pain on 11-point scale compared to 1.4 points for placeboes. The difference was statistically important. Those receiving medicines also reported to improve sleep and physical work.
Patients continuing with a six -month expansion phase continued to experience pain decrease. The results were published in Journal Nature on Monday.
Side effects included dizziness, headache, fatigue and nausea and more than 17% of people stopped the drug quickly. Researchers stated that the dropout rate was usually less than reported with opioids, which could lead to constipation, nausea, drowsiness and drug addiction.
Warticle has filed an application for its medicine with European regulators. In the US, the company says that it is “closely working” with regulators to design a study to support FDA approval.
The Associated Press Health and Science Department receives support from the Department of Science Education and Robert Wood Johnson Foundation of Howard Hughes Medical Institute. AP is completely responsible for all materials.
